Mesoblast Limited announced Ryoncil net revenue of US$36 million for the fourth quarter ended June 30, 2026, with full-year revenue reaching US$115 million. The company cited strong uptake across major U.S. pediatric centers as the primary driver for the results, which exceeded initial projections. Chief Executive Dr. Silviu Itescu highlighted the momentum, stating that operational activities are well funded through revenue growth and a new five-year facility has freed up capital for strategic initiatives involving label extension and blockbuster products.

Ryoncil is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food and Drug Administration (FDA) for any indication. It remains the only FDA-approved treatment for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD). The product is also being developed for additional inflammatory diseases, including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease.

Financial Performance

The revenue figures are based on management’s preliminary estimates and remain subject to completion of customary year-end closing and audit procedures. The company’s capital position is reported as strong, with operational activities funded by the revenue growth observed during the period.

Strategic Outlook

Mesoblast anticipates continued revenue growth in the coming fiscal year, aligning with current momentum in pediatric centers. The company is also advancing its rexlemestrocel-L platform for heart failure and chronic low back pain. Commercial partnerships have been established in Japan, Europe, and China to support global expansion.

Mesoblast Limited has received a Biologics License Application (BLA) filing number from the U.S. Food and Drug Administration (FDA) and has requested a modular review of its application for rexlemestrocel-L. The therapy is intended for the prevention of life-threatening gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device (LVAD). This regulatory step is significant for patients with high mortality and irreversible morbidity associated with orphan rare diseases.

The FDA recently provided additional guidance regarding regulatory flexibility for products addressing rare diseases. The new draft guidance, titled ‘Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products’, emphasizes a flexible approach to substantial evidence of effectiveness. This follows a May guidance titled ‘Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application.’

Rexlemestrocel-L has received Orphan Drug Designation for the prevention of life-threatening major mucosal bleeding events. It also holds Regenerative Medicine Advanced Therapy (RMAT) designation for this patient population, which provides eligibility for rolling and priority reviews of the BLA. Mesoblast Chief Executive Dr. Silviu Itescu stated that the company looks forward to working closely with the FDA to make the therapy available for end-stage heart failure patients on mechanical devices who are at high risk of life-threatening gastrointestinal bleeding.

The investigational therapy is an allogeneic preparation of immunoselected and culture-expanded mesenchymal precursor cells (MPC). It is being developed as an immunomodulatory therapy to address inflammation in the heart and circulation across the spectrum of heart failure and reduced ejection fraction (HFrEF) patients. The goal is to reduce the rate of major cardiac events and complications.

Rexlemestrocel-L has been trialled in two large placebo-controlled randomized studies in patients with chronic heart failure (CHF). These include a 565-patient trial in New York Heart Association (NYHA) class II/III HFrEF patients and a 159-patient trial in end-stage HFrEF patients implanted with an LVAD. The therapy has FDA RMAT and Orphan Drug designations for patients with end-stage HFrEF implanted with an LVAD.

Chronic heart failure affects approximately 6.5 million people in the United States and 26 million people globally. The mortality rate approaches 50% at 5 years as patients progress beyond NYHA early class II disease. Every year in the United States, over 100,000 patients progress to end-stage HFrEF, with a one-year mortality as high as 50%. In these patients, more than 2,500 life-prolonging LVADs are implanted in the US annually.